Serum Insulin‐Like Growth Factor‐1 (IGF‐1) in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Brain and Behavior · 2026-11 · 16 (11)
DOI: 10.1002/brb3.71872 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Brain and Behavior, online erschienen am 05.11.2026. Verfasst von Sajjad Mahdavi und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Parkinson Disease, Insulin-Like Growth Factor I. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by progressive motor and non‐motor symptoms. Insulin‐like Growth Factor‐1 (IGF‐1), a neuroprotective hormone, has been proposed as a potential biomarker in PD.
Objectives
This study aimed to evaluate differences in serum IGF‐1 levels between people with PD (PwPD) and healthy controls, and to assess associations with symptom severity.
Methods
We conducted a systematic search of PubMed, Embase, and Web of Science on December 7, 2024. Observational studies comparing serum IGF‐1 in PwPD and healthy controls, or assessing its associations with PD symptoms, were included. Study quality was evaluated using the Newcastle–Ottawa Scale. A random‐effects meta‐analysis pooled mean differences (MD) in IGF‐1 levels, and correlation coefficients were synthesized for motor symptoms. Non‐motor symptom associations were analyzed using effect direction plots.
Results
Eighteen studies with 2,480 participants (1,465 PwPD; 1,015 controls) were included. PwPD had significantly higher serum IGF‐1 levels than controls (MD: 21.3 ng/mL; 95CI: 11.49, 31.12; p < 0.001). Elevated IGF‐1 was consistent across early/late‐stage and drug‐naïve/treated PwPD, with no significant subgroup differences. Meta‐analysis of five studies (413 PwPD) showed an inverse correlation between IGF‐1 levels and motor symptom severity ( r = −0.35; 95% CI: −0.53, −0.08; p < 0.01), although individual study findings were heterogeneous, and the certainty of evidence was low. Non‐motor symptoms also showed no consistent associations.
Conclusions
PwPD exhibit elevated serum IGF‐1 levels and may be inversely associated with motor symptom severity. IGF‐1's relationship with non‐motor symptoms remains unclear and requires further study. Longitudinal research is needed to determine IGF‐1's utility as a PD biomarker
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Sajjad Mahdavi, Shahryar Rajai Firouzabadi, Ida Mohammadi, Soroush Oraee, Mohammadreza Alinejadfard, Seyed Ali Mofidi, Ehsan Sharifipour
Zitieren
APA
Mahdavi, S., Rajai Firouzabadi, S., Mohammadi, I., Oraee, S., Alinejadfard, M., Mofidi, S. A., Salari, M., & Sharifipour, E. (2026). Serum Insulin‐Like Growth Factor‐1 (IGF‐1) in Parkinson's Disease: A Systematic Review and Meta‐Analysis. Brain and Behavior, 16(11). https://doi.org/10.1002/brb3.71872
Vancouver
Mahdavi S, Rajai Firouzabadi S, Mohammadi I, Oraee S, Alinejadfard M, Mofidi SA, et al. Serum Insulin‐Like Growth Factor‐1 (IGF‐1) in Parkinson's Disease: A Systematic Review and Meta‐Analysis. Brain and Behavior. 2026;16(11). doi:10.1002/brb3.71872
BibTeX
@article{Mahdavi2026,
author = {Mahdavi, Sajjad and Rajai Firouzabadi, Shahryar and Mohammadi, Ida and Oraee, Soroush and Alinejadfard, Mohammadreza and Mofidi, Seyed Ali and Salari, Mehri and Sharifipour, Ehsan},
title = {Serum Insulin‐Like Growth Factor‐1 (IGF‐1) in Parkinson's Disease: A Systematic Review and Meta‐Analysis},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {11},
doi = {10.1002/brb3.71872}
}
EUVIMED